Bright Minds Biosciences Inc.
Price Action
Technical Summary
EMERGING TRENDBright Minds Biosciences Inc. is attempting to emerge into an uptrend but lacks full moving average alignment. Relative strength is leading (RS Rating: 83), indicating clear outperformance against the broad market. Earnings contraction of 141% provides fundamental context to the price action. Investors should exercise caution due to high volatility (70% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $88.13 | +0.77% | ABOVE |
| 50 SMA | $80.71 | +10.05% | ABOVE |
| 100 SMA | $82.17 | +8.08% | ABOVE |
| 150 SMA | $75.70 | +17.32% | ABOVE |
| 200 SMA | $67.52 | +31.54% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is DRUG in an uptrend right now?
DRUG has a trend score of 3/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 3 of 4 trend criteria are met.
Is DRUG overbought or oversold?
DRUG's RSI (14) is 58. The stock is in neutral territory, neither overbought nor oversold.
Is DRUG outperforming the market?
DRUG has a Relative Strength (RS) Rating of 83 out of 99. Yes, DRUG is a market leader, outperforming 83% of all stocks over the past 12 months.
Where is DRUG in its 52-week range?
DRUG is trading at $88.81, which is 72% of its 52-week high ($123.75) and 65% above its 52-week low ($23.18).
How volatile is DRUG?
DRUG has a Beta of 1.87 and 52-week volatility of 70%. It's more volatile than the S&P 500 - expect bigger swings.